ENG/中
老虎证券
行情
交易
收费
下载
优惠与活动
帮助
TigerAI
机构
财富及资产管理人
自营交易机构
介绍经纪商
三方服务商
股权激励
关于
登录
立即注册
Toggle
美股
详情
本页面由Tiger Trade Technology Pte. Ltd.提供服务
Xtrackers Nifty 500 India ETF
24.65
+0.1150
0.47%
成交量:
333.00
成交额:
8,196.89
市值:
493.00万
市盈率:
- -
高:
24.65
开:
24.58
低:
24.58
收:
24.54
52周最高:
27.40
52周最低:
23.33
股本:
20.00万
流通股本:
20.00万
量比:
0.04
换手率:
0.17%
股息:
- -
股息率:
- -
净资产收益率:
--
总资产收益率:
--
市净率:
--
市盈率(LYR):
- -
数据加载中...
总览
公司
新闻资讯
公告
概念
没有相关数据
资金流向
资金流入:
资金流出:
实时
日
周
月
季度
年
新闻资讯
九源基因(02566):JY54注射液IND申请获CDE正式受理
智通财经
·
昨天
亚盛医药BTK降解剂APG-3288新药临床申请(IND)获CDE许可,全球临床开发再提速
美通社
·
02/06
友芝友生物-B(02496):M 701取得FDA的IND批准
智通财经
·
02/03
前沿生物:2025年末公司已就FB7013向国家药监局提交IND申请并获受理,FB7013正式进入临床申请审批通道
证券日报
·
01/26
{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券 | 轻松买卖美股港股A股/美债/ETF/Crypto/期权期货","description":"老虎证券提供多项优惠: 港股&Crypto 0佣0平台费、A股通一年免佣、美股期权0佣、IPO打新0融资利息0手续费。 美股1美元起投,免费实时行情与多种工具,立即开户享更多优惠!","keywords":"老虎证券,老虎证券开户,老虎证券香港,老虎证券登录,老虎证券官网,香港证券开户,证券公司开户,股票开户,香港证券公司,香港证券,证券公司,股票投资,投资app,投资平台,股票买卖,股票交易平台,股票app,证券app,新手投资","social":{"ogDescription":"老虎证券提供多项优惠: 港股&Crypto 0佣0平台费、A股通一年免佣、美股期权0佣、IPO打新0融资利息0手续费。 美股1美元起投,免费实时行情与多种工具,立即开户享更多优惠!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/stock/IND"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"IND","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IND\",,,,,undefined,":{"symbol":"IND","market":"US","secType":"STK","nameCN":"Xtrackers Nifty 500 India ETF","latestPrice":24.65,"timestamp":1770659766499,"preClose":24.535,"halted":0,"volume":333,"delay":0,"changeRate":0.004687181577338433,"floatShares":200001,"shares":200001,"eps":0,"marketStatus":"交易中","change":0.115,"latestTime":"02-09 13:10:48 EST","open":24.58,"high":24.65,"low":24.58,"amount":8196.892902,"amplitude":0.002853,"askPrice":24.63,"askSize":100,"bidPrice":24.45,"bidSize":100,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1770670800000},"marketStatusCode":2,"adr":0,"exchange":"NASDAQ","adjPreClose":24.535,"sharesOutstanding":200001,"nav":24.236,"aum":4847319.35,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":24.53,"preClose":24.535,"latestTime":"16:04 EST","volume":1,"amount":24.535,"timestamp":1770411858205,"change":-0.005,"changeRate":-0.000204,"amplitude":0},"volumeRatio":0.039488},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IND\",,,,,undefined,":{"symbol":"IND","floatShares":200001,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.039488,"shares":200001,"dividePrice":0,"high":24.65,"amplitude":0.002853,"preClose":24.535,"low":24.58,"week52Low":23.3301,"pbRate":"--","week52High":27.4,"institutionHeld":0,"latestPrice":24.65,"eps":0,"divideRate":0,"volume":333,"delay":0,"ttmEps":0,"open":24.58,"prevYearClose":24.78,"prevWeekClose":24.535,"prevMonthClose":23.8555,"prevQuarterClose":24.78,"fiveDayClose":24.7868,"twentyDayClose":24.5796},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/IND\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"IND\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"IND\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"IND\",pageSize:4,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2610600638","title":"九源基因(02566):JY54注射液IND申请获CDE正式受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2610600638","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610600638?lang=zh_cn&edition=fundamental","pubTime":"2026-02-09 16:56","pubTimestamp":1770627414,"startTime":"0","endTime":"0","summary":"智通财经APP讯,九源基因 发布公告,公司自主开发的化学1类创新药JY54 注射液新药临床试验申请,已获国家药品监督管理局药品审评中心正式受理。JY54注射液是公司自主研发的一款长效胰淀素类似物。此外,在与已上市肥胖治疗药物的联合应用研究中,JY54注射液展现出显著的药物协同潜力。基于其分子设计特点及作用机制分析,JY54注射液有望支持长效给药方案,并在体重管理领域展现差异化的临床应用潜力。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1403166.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1223082196.USD","02566","BK4017","IND","LU1223082519.USD","LU1223083913.SGD","BK1161","CDE"],"gpt_icon":0},{"id":"2609095558","title":"亚盛医药BTK降解剂APG-3288新药临床申请(IND)获CDE许可,全球临床开发再提速","url":"https://stock-news.laohu8.com/highlight/detail?id=2609095558","media":"美通社","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609095558?lang=zh_cn&edition=fundamental","pubTime":"2026-02-06 10:04","pubTimestamp":1770343440,"startTime":"0","endTime":"0","summary":"美国马里兰州罗克维尔市和中国苏州2026年2月6日 /美通社/ -- 致力于在肿瘤等领域开发创新药物的领先的生物医药企业——亚盛医药宣布,公司自主研发的原创新一代布鲁顿酪氨酸激酶靶向蛋白降解剂APG-3288的新药临床申请日前已获国家药品监督管理局药品审评中心许可,拟开发用于治疗复发/难治性血液系统恶性肿瘤。此前,该药物已获美国FDA许可开展临床试验。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://wwwold.prnasia.com/story/archive/4882324_ZH82324_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["CDE","LU2125909916.SGD","LU1223083913.SGD","LU1923622291.USD","BK4017","LU1223082196.USD","AAPG","BK4144","LU1223082519.USD","APG","LU2125909759.SGD","TK","BK1161","06855","BK4139","IND","BK1574","BK4129"],"gpt_icon":0},{"id":"2608824493","title":"友芝友生物-B(02496):M 701取得FDA的IND批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2608824493","media":"智通财经","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608824493?lang=zh_cn&edition=fundamental","pubTime":"2026-02-03 18:09","pubTimestamp":1770113353,"startTime":"0","endTime":"0","summary":"智通财经APP讯,友芝友生物-B 发布公告,于2026年1月31日,注射用重组抗上皮细胞黏附分子和分化簇3人鼠嵌合双特异性抗体获美国食品药物管理局临床试验申请批准,标志着这款针对恶性胸腔积液的创新疗法迈入国际化临床开发新阶段,为全球患者带来新希望。M 701精准靶向Ep CAM和CD3,其中Ep CAM在上皮来源恶性胸腔积液肿瘤细胞中高频表达,是关键治疗靶点;CD3可激活机体抗肿瘤免疫,二者协同实现精准治疗。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1401100.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IND","BK1161","02496"],"gpt_icon":0},{"id":"2606243834","title":"前沿生物:2025年末公司已就FB7013向国家药监局提交IND申请并获受理,FB7013正式进入临床申请审批通道","url":"https://stock-news.laohu8.com/highlight/detail?id=2606243834","media":"证券日报 ","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606243834?lang=zh_cn&edition=fundamental","pubTime":"2026-01-26 20:05","pubTimestamp":1769429100,"startTime":"0","endTime":"0","summary":"关于BD合作事宜,公司始终秉持开放的态度,积极探索符合产品发展战略的合作机会。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2026-01-26/doc-inhirukv8982872.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2026-01-26/doc-inhirukv8982872.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["IND","BK0239","688221"],"gpt_icon":0}],"pageSize":4,"totalPage":6,"pageCount":1,"totalSize":23,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/IND\",params:#limit:6,delay:false,,,undefined,":[]}}